Loading…
← CockpitCompetitor Analysis › RGNX REGENXBIO, Inc.Open in the cockpit ↗

REGENXBIO, Inc.RGNXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum neutral 41
Mkt cap
$480M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$9.23M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-107.5 pp
WACC 9.3%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$7.26
1D+0.3%
1W-14.3%
1M-1.9%
3M-34.4%
6M+21.6%
YTD-49.6%
1Y-34.8%
ATR %8.0%
Beta1.76
52w lowhigh55.2% off high

What REGENXBIO does

Employees: 371

REGENXBIO at a glance

Size REGENXBIO (RGNX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $480M, the 2697th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.26 on 18 Nov 2026.

Performance Over six months the shares gained 21.6%, against -14.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 4.6% over the last twelve months (peer median +11.0%); the operating margin is -120.4% (peer median 10.9%).

Valuation It trades at 3.1× enterprise value to sales against a peer median of 4.3× (8th cheapest of 20).

Capital Return on invested capital runs 107.5 points below its cost of capital (9.3% WACC).

Short interest Short interest is 15.4% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026RGNX 108Peer median 86
Six months, rebased to 100: REGENXBIO against the median of its 20 peers (local-currency closes).

REGENXBIO financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$154M$170M$83.3M$90.2M$113M
Revenue growth—+105%-8%-20%—
Gross profit$120M$135M$33.5M$35.7M$45.3M
EBITDA-$170M-$146M-$215M-$251M-$250M
Net income-$175M-$194M-$227M-$263M-$280M
Free cash flow-$155M-$126M-$176M-$228M-$238M
Capital expenditure$2.70M$2.41M$2.44M$9.96M$30.7M
Total debt$252M$261M$142M$89.3M$94.8M

Quarterly statements and history in the cockpit →

REGENXBIO competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%HNSA688373600624SMSPHARMAAQST003020300584370530127730120116666620EOLS002107002370CAPRKPLAARTIDRUGS003090600513RGNX6-month return →1-month return →
Up and to the right = strong over both horizons. REGENXBIO is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×10×20×HNSA688373600624SMSPHARMAAQST003020300584370530127730120116666620EOLS002107002370KPLAARTIDRUGS003090RGNXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. REGENXBIO is the large dot.

REGENXBIO competitors and peer comparison

How REGENXBIO compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

REGENXBIO against its 20 peers (data as of 18 Nov 2026)
MeasureRGNXPeer medianRank in peer set
1-month return-1.9%-3.4%9th highest of 21
6-month return+21.6%-14.4%5th highest of 21
Distance from 52-week high-55.2%-36.8%5th lowest of 21
Revenue growth (TTM)-4.6%+11.0%6th lowest of 21
Operating margin-120.4%10.9%2nd lowest of 20
EV / Sales3.1×4.3×8th cheapest of 20
ROIC minus cost of capital-107.5 pp-2.6 pp2nd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a

Questions

Which companies are REGENXBIO's closest peers?
The cockpit's peer set: Hansa Biopharma (HNSA.ST), Shanghai MicuRx Pharmaceutical (688373.SS), Shanghai Fudan Forward S&T (600624.SS), SMS Pharmaceuticals (SMSPHARMA.NS), Aquestive Therapeutics (AQST), Hefei Lifeon Pharmaceutical (003020.SZ), Nanjing Hicin Pharmaceutical (300584.SZ), YungShin Global (3705.TW).
Is REGENXBIO expensive compared with its peers?
On ev / sales it trades at 3.1× against a peer median of 4.3×, 8th cheapest of 20 in its peer set.
How has REGENXBIO stock performed?
Over six months to 18 Nov 2026 the shares returned +21.6% against -14.4% for the median peer; over one year -34.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.